ExaGrid, Provider of Intelligent Hyperconverged Storage for Backup, Reports Record Annual Revenue for 2018
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced record revenue for the full year of 2018. ExaGrid’s revenue grew 20% in 2018 over 2017. The company is growing faster than the overall market and continues to grow its market share position. Demonstrating growing demand on the part of enterprise IT environments for a superior solution that’s also cost effective, ExaGrid added over 100 new customers in the 4th quarter of 2018
“ExaGrid had an excellent year in North America, Latin America, EMEA and APAC,” said Bill Andrews, CEO and President of ExaGrid. “We are gaining momentum as our growth percentages demonstrate. In 2016, ExaGrid reported 12.2% growth; in 2017, 14.5%; and in 2018, 20%. The corporate goal is a growth rate of 25% in 2019 and 30% in 2020.” ExaGrid has continued to added global sales teams and now covers over 30 countries worldwide. The company will continue to expand its global reach with the goal of covering over 50 countries in 2020.
Andrews reports that customers in record numbers are turning to ExaGrid out of frustration with poor performance and excessive cost incurred when using disk behind backup applications with deduplication. Similar performance and cost complaints are heard from customers using inline deduplication products such as Dell EMC Data Domain and HPE StoreOnce. ”ExaGrid’s unique scale-out architecture with a landing zone and adaptive deduplication beats every solution on the market when it comes to backup performance, restore performance, cost up front, and cost over time. In addition, ExaGrid eliminates forklift upgrades and product obsolescence.”
For the year 2018, ExaGrid reports the following results:
- Achieved a record bookings and revenue year as well as a record number of six-figure new customer opportunities.
- Relocated corporate offices and continued global expansion with addition of field sales teams in Europe, the Middle East, Africa, APAC, and Latin America.
Customer recognition / industry awards
- Customer survey yielded a Net Promoter Score of +73, considered to be “excellent” by Net Promoter standards.
- Voted “Product of the Year, Hyper-converged Backup and Recovery” by SVC Awards.
- Named “Company of the Year, Hyper-converged Backup and Recovery” in the 2018 Storries XVI Awards.
- Rated “Recommended Deduplicating Backup Appliance” in DCIG’s 2018 buyer’s guide.
- Began shipping the EX63000E that scales to a 2PB full backup in a single system with an ingest rate of over 400TB per hour and supports a replicated second site with storage of up to 4PB for disaster recovery and long-term retention, making it the largest and fastest system on the market.
- Increased its partnership with Veeam participating in well over 100 joint marketing campaigns and events in 2018.
- Announced a new strategic alliance with HYCU for purpose-built support of Nutanix environments using VMware or AHV hypervisors.
ExaGrid is the only provider of intelligent hyperconverged storage for backup that overcomes the three compute challenges of backup storage with data deduplication. All backup storage and backup software vendors reduce storage and bandwidth to varying degrees but are impaired by sluggish ingest rates due to the fact that they perform data deduplication ‘inline.’ In addition, because they only store deduplicated data, restore speeds and VM boots are also very slow. Deduplication that is built into the backup software is far less aggressive, uses a larger amount of disk, and is much slower for backups and restores.
ExaGrid’s ingest is 3 times faster - and restores/VM boots are up to 20 times faster - than its closest competitor. In addition, since each ExaGrid appliance that is added to an existing system brings compute with capacity, the backup window remains fixed in length even as data grows. Only ExaGrid uses a scale-out architecture with a unique loading zone, which addresses all of the scalability and performance challenges of backup storage. ExaGrid not only delivers the fastest backups and restores, but is the only solution that truly scales, provides a fixed length backup window as data grows, and eliminates forklift upgrades as well as product obsolescence.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate high customer satisfaction with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at www.exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CES Unveiled in Amsterdam to Showcase Tech for Good19.8.2019 07:00:00 CEST | Press release
Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA)® today announced several government officials, dignitaries and industry leaders attending CES Unveiled in Amsterdam, an official CES preview event, focusing on the theme “Tech for Good.” Returning for its third year, CES Unveiled in Amsterdam will bring together executives, influential media, prominent industry influencers, and more than 100 companies (including 50+ startups) to explore the latest technology trends and innovations from the Netherlands and surrounding European countries leading up to CES® 2020. Attendees and media are able to register for CES Unveiled in Amsterdam online. WHO: Government officials and dignitaries including Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL; and Pete Hoekstra, U.S. Ambassador to the Netherlands, will share insights on emerging trends in the industry, includi
RISO Unveils VALEZUS, a New Brand for the Production-printing Market19.8.2019 06:00:00 CEST | Press release
RISO KAGAKU CORPORATION (President & CEO: Akira Hayama; hereinafter “RISO”) announced today the launch of VALEZUS, a new brand of high-speed ink-jet printers for the production-printing market. RISO will start with successive rollouts worldwide of the new brand’s first product, the VALEZUS T2100, a high-speed, 320-page-per-minute (320-ppm) cut-sheet printer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190818005001/en/ 1 The new brand, VALEZUS One of RISO’s commanding strengths is the development of inks optimized for high-speed paper feeding and high-speed printing. This expertise enables RISO to deliver unique printing solutions serving the demand for high-volume printing. With technologies developed and cultivated in this field, RISO launches the VALEZUS, a fresh brand targeting the production-printing market. 2 The all-new VALEZUS T2100 VALEZUS T2100 The first product of the new brand, the VALEZUS T2100 is a high-speed
Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 12:00:00 CEST | Press release
Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques
Merz Announces Key Governance Changes16.8.2019 09:26:00 CEST | Press release
Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae
FINEOS lists on the Australian Securities Exchange16.8.2019 07:22:00 CEST | Press release
FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 20:01:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem